gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 25 Jul 2015.

Apolipoprotein A-Ia

apolipoprotein A-I, apoA-I
Top mentioned proteins: HDL, Apo, CAN, HAD, fibrillin-1
Papers on apolipoprotein A-I
Vascular alterations in apolipoprotein A-I amyloidosis (Leu75Pro). A case-control study.
Agabiti Rosei et al., Brescia, Italy. In Amyloid, 21 Aug 2015
BACKGROUND: Among hereditary amyloidoses, apolipoprotein A-I (APO A-I) amyloidosis (Leu75Pro) is a rare, autosomal dominant condition in which renal, hepatic, and testicular involvement has been demonstrated.
Deficiency in the lipid exporter ABCA1 impairs retrograde sterol movement and disrupts sterol sensing at the endoplasmic reticulum.
Yokoyama et al., Nagoya, Japan. In J Biol Chem, 20 Aug 2015
ATP-binding cassette transporter A1 (ABCA1) mediates cholesterol and phospholipid export to apolipoprotein A-I for the assembly of high-density lipoprotein (HDL).
Amyloidogenic Mutation Promotes Fibril Formation of the N-terminal Apolipoprotein A-I on Lipid Membranes.
Saito et al., Tokushima, Japan. In J Biol Chem, 14 Aug 2015
UNASSIGNED: The N-terminal amino acids 1-83 fragment of apolipoprotein A-I (apoA-I) has a strong propensity to form amyloid fibrils at physiological neutral pH.
Increasing HDL levels by inhibiting cholesteryl ester transfer protein activity in rabbits with hindlimb ischemia is associated with increased angiogenesis.
Rye et al., Sydney, Australia. In Int J Cardiol, 11 Aug 2015
increased plasma apoA-I levels by 1.3±0.1-
Regulation of thrombosis and vascular function by protein methionine oxidation.
Lentz et al., Iowa City, United States. In Blood, 18 Jul 2015
Several other proteins with oxidation-sensitive methionine residues, including apolipoprotein A-I, thrombomodulin, and von Willebrand factor, may contribute to vascular disease and thrombosis.
Lipid-free Apolipoprotein A-I Structure: Insights into HDL Formation and Atherosclerosis Development.
Atkinson et al., Boston, United States. In Arch Med Res, 02 Jul 2015
Knowledge of the high-resolution structure of full-length apoA-I is vital for a molecular understanding of the function of HDL at the various steps of the RCT pathway.
Innovative pharmaceutical interventions in cardiovascular disease: focusing on the contribution of non-HDL-C/ LDL-C-lowering versus HDL-C-raising A systematic review and meta-analysis of relevant preclinical studies and clinical trials.
Wouter Jukema et al., Leiden, Netherlands. In Eur J Pharmacol, 16 Jun 2015
Nonetheless, treatment strategies aimed at improving HDL function and raising apolipoprotein A-I may be worth exploring.
Structural stability and functional remodeling of high-density lipoproteins.
Gursky, Boston, United States. In Febs Lett, Apr 2015
A mechanism for the conformational adaptation of the major HDL proteins, apoA-I and apoA-II, to the increasing lipid load is proposed.
The Human Autoantibody Response to Apolipoprotein A-I Is Focused on the C-Terminal Helix: A New Rationale for Diagnosis and Treatment of Cardiovascular Disease?
Hartley et al., Genève, Switzerland. In Plos One, Dec 2014
Autoantibodies directed against apolipoprotein A-I (ApoA-I) represent promising biomarkers for use in risk stratification of CVD and may also play a direct role in pathogenesis.
ApoA-I mimetics.
Hovingh et al., Amsterdam, Netherlands. In Handb Exp Pharmacol, Dec 2014
ApoA-I, the major protein component of HDL, is considered to play an important role in many of the antiatherogenic functions of HDL, most notably reverse cholesterol transport (RCT), and several therapies have been developed to mimic apoA-I function, including administration of apoA-I, mutated variants of apoA-I, and apoA-I mimetic peptides.
Plasma lipids, genetic variants near APOA1, and the risk of infantile hypertrophic pyloric stenosis.
Melbye et al., Copenhagen, Denmark. In Jama, 2013
P = 1.9 × 10(-10)), is located 301 bases downstream of the apolipoprotein A-I (APOA1) gene and is correlated (r2 between 0.46 and 0.80) with SNPs previously found to be associated with levels of circulating cholesterol.
Control of angiogenesis by AIBP-mediated cholesterol efflux.
Miller et al., San Diego, United States. In Nature, 2013
To prevent cholesterol overload, ATP-binding cassette (ABC) transporters mediate cholesterol efflux from the cells to apolipoprotein A-I (apoA-I) and the apoA-I-containing high-density lipoprotein (HDL).
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival.
Singh-Jasuja et al., Tübingen, Germany. In Nat Med, 2012
Furthermore, among six predefined populations of myeloid-derived suppressor cells, two were prognostic for overall survival, and among over 300 serum biomarkers, we identified apolipoprotein A-I (APOA1) and chemokine (C-C motif) ligand 17 (CCL17) as being predictive for both immune response to IMA901 and overall survival.
Lipid-related markers and cardiovascular disease prediction.
Danesh et al., In Jama, 2012
OBJECTIVE: To determine whether adding information on apolipoprotein B and apolipoprotein A-I, lipoprotein(a), or lipoprotein-associated phospholipase A2 to total cholesterol and high-density lipoprotein cholesterol (HDL-C) improves cardiovascular disease (CVD) risk prediction.
Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis.
Rader et al., Philadelphia, United States. In N Engl J Med, 2011
RESULTS: The levels of HDL cholesterol and apolipoprotein A-I were significant determinants of cholesterol efflux capacity but accounted for less than 40% of the observed variation.
Rapid incorporation of functional rhodopsin into nanoscale apolipoprotein bound bilayer (NABB) particles.
Sakmar et al., New York City, United States. In J Mol Biol, 2008
The NABB system using engineered zebrafish apo A-I is a native-like membrane mimetic system for G-protein-coupled receptors.
share on facebooktweetadd +1mail to friends